Randox Cystatin C facilitates early detection and treatment of chronic kidney disease
Published on July 22, 2014 at 5:20 AM
As a more sensitive maker of renal dysfunction Randox Cystatin C offers several advantages over traditional creatinine assays. Unlike creatinine tests, Randox Cystatin C is virtually unaffected by non-renal factors including muscle mass, weight, height, age, gender, diet and drugs. This makes it particularly useful in cases where creatinine measurement is not appropriate e.g. in individuals who are obese, malnourished, who have liver disease or in infants and the elderly.
An additional benefit delivered by Randox Cystatin C is that it facilitates the early detection and treatment of chronic kidney disease due to the fact Cystatin C is highly sensitive to even small changes in Glomerular Filtration Rate (GFR). Furthermore, Randox Cystatin C does not suffer from a 'blind area', like creatinine based testing. The 'blind range' associated with creatinine testing can mean a high percentage of kidney function is lost before elevation of this analyte occurs. Randox Cystatin C however, is capable of detecting early reductions in GFR, therefore providing more accurate results and supporting the prompt treatment of kidney disease.
Randox Cystatin C Key Assay Details
•Liquid ready-to-use reagents
•Latex enhanced immunoturbidimetric assay
•Extensive measuring range- 0.4-10mg/l
•On-board stability of 28 days at +10°C
•Instrument Specific Applications available for an extensive range of clinical chemistry analyzers